Key Takeaways
What Are the Most Common ADHD Medication Side Effects?
The most common ADHD medication side effects are loss of appetite, trouble sleeping, headache, stomachache, irritability, a fast heart rate and high blood pressure, according to the U.S. Food and Drug Administration[6]. That list covers prescription stimulants used for ADHD, including methylphenidate (Ritalin, Concerta) and amphetamine (Adderall, Dexedrine)[6].
Placebo-controlled trials show how much of this the drug itself causes. In a 4-week FDA registration trial of lisdexamfetamine (Vyvanse) in children aged 6 to 12, 39% reported decreased appetite compared with 4% on placebo, and 22% reported insomnia compared with 3%[1].
The largest review of methylphenidate in young people, a 2023 Cochrane review of 212 trials with 16,302 participants, found the drug may increase non-serious adverse events (risk ratio 1.23)[2]. It found no clear difference in serious adverse events (risk ratio 0.80, 95% confidence interval 0.39 to 1.67)[2].
The Cochrane authors rated the certainty of the evidence for all outcomes as very low, so the true size of these effects is unclear[2]. For how the drug classes compare on effectiveness, see the overview of ADHD meds; for how many people take them, see ADHD medication statistics.
How Side Effects Differ in Children, Teens and Adults
Side effects shift with age. Decreased appetite dominates in children, while adults on Vyvanse reported dry mouth almost as often as appetite loss: 26% compared with 3% on placebo[1].
Adults in the Vyvanse trial also reported anxiety (6% vs. 0%), feeling jittery (4% vs. 0%) and increased blood pressure (3% vs. 0%)[1]. Erectile dysfunction was observed in 2.6% of men on Vyvanse and none on placebo[1].
Children showed more stomach and mood effects. Upper abdominal pain was reported by 12% of children aged 6 to 12 on Vyvanse vs. 6% on placebo, and irritability by 10% vs. 0%[1]. Affect lability, meaning rapid shifts in mood, appeared in 3% vs. 0%, and tics in 2% vs. 0%[1].
How often side effects lead people to stop
In the pediatric Vyvanse trial, 8% of children on the drug stopped because of adverse reactions, compared with 0% on placebo[1]. In the adult trial the figures were 6% and 2%[1].
Vyvanse Side Effects vs. Placebo by Age Group
| Side effect | Children 6-12 | Teens 13-17 | Adults |
|---|---|---|---|
| Decreased appetite | 39% vs. 4% | 34% vs. 3% | 27% vs. 2% |
| Insomnia | 22% vs. 3% | 13% vs. 4% | 27% vs. 8% |
| Dry mouth | 5% vs. 0% | 4% vs. 1% | 26% vs. 3% |
| Upper abdominal pain | 12% vs. 6% | - | - |
| Irritability | 10% vs. 0% | - | - |
| Weight decreased | 9% vs. 1% | 9% vs. 0% | 3% vs. 0% |
| Nausea | 6% vs. 3% | - | 7% vs. 0% |
| Anxiety | - | - | 6% vs. 0% |
| Increased blood pressure | - | - | 3% vs. 0% |
| Tic | 2% vs. 0% | - | - |
Share of participants reporting each adverse reaction on lisdexamfetamine (Vyvanse) vs. placebo in 4-week trials: children 6-12 (218 vs. 72), teens 13-17 (233 vs. 77), adults (358 vs. 62)[1].
1A dash means the reaction was not listed for that age group; the label lists only reactions reported by at least 2% of Vyvanse users and at least twice as often as on placebo[1].
Sources
- •FDA, Vyvanse prescribing information, 2026
Children aged 6 to 12 on Vyvanse who reported decreased appetite in a 4-week trial, vs. 4% on placebo
Appetite loss was the most common side effect in every age group in the Vyvanse trials, and in children it was nearly 10 times the placebo rate.
"Decreased Appetite | 39% | 4%"
Side Effects of Non-Stimulants: Strattera, Guanfacine and Others
Non-stimulants have their own profile. In adult trials of atomoxetine (Strattera), the most frequent adverse reactions were nausea (26% vs. 6% on placebo), dry mouth (20% vs. 5%) and decreased appetite (16% vs. 3%)[7].
Atomoxetine also showed sexual and urinary effects in adults: erectile dysfunction in 8% vs. 1%, and urinary hesitation in 6% vs. 1%[7]. Insomnia was reported by 15% vs. 8%, and sleepiness by 8% vs. 5%[7].
Atomoxetine carries an FDA boxed warning for suicidal thoughts in children and teens. Across 12 short-term pediatric studies, suicidal ideation was reported in 0.4% of patients on the drug (5 of 1,357) compared with 0% on placebo (0 of 851), and no suicides occurred[7]. The label calls for close monitoring, especially in the first months of treatment or after a dose change[7].
Guanfacine works in the opposite direction on the heart: it lowered blood pressure and pulse in trials rather than raising them[3]. Its sleepiness and blood pressure effects are covered in detail in the post on Intuniv for ADHD.
Boxed warning
A boxed warning is the most prominent safety warning in a U.S. prescribing label, printed in a box at the top of the label. For ADHD stimulants it now describes the risks of misuse, abuse, addiction and overdose consistently across every medicine in the class[6]. Atomoxetine carries a separate boxed warning for suicidal thoughts and behaviors in pediatric patients[7].
Related Terms
Source: U.S. Food and Drug Administration
How ADHD Medications Affect Heart Rate and Blood Pressure
The most complete comparison is a 2025 network meta-analysis in The Lancet Psychiatry[3]. It pooled 102 randomized trials covering 13,315 children and adolescents and 9,387 adults, with a median follow-up of 7 weeks[3].
Amphetamines, lisdexamfetamine, methylphenidate, atomoxetine and viloxazine all raised blood pressure, pulse or both[3]. In children and adolescents, pulse rose by 2.79 beats per minute with viloxazine up to 5.58 beats per minute with atomoxetine, compared with placebo[3].
Stimulants did not raise these values more than the non-stimulants atomoxetine and viloxazine[3]. The authors concluded that blood pressure and pulse should be monitored with any ADHD medication, not stimulants only[3].
The evidence is short-term. Only four trials reported effects in the medium term and none in the long term[3]. Averages of a few points can also hide larger increases in individual patients.
Average Blood Pressure and Pulse Change vs. Placebo, by Drug
| Medication | Systolic BP (mm Hg) | Diastolic BP (mm Hg) | Pulse (bpm) |
|---|---|---|---|
| Methylphenidate (children) | +1.81 | +2.42 | - |
| Atomoxetine (children) | +1.07 | - | +5.58 |
| Amphetamines (children) | - | +1.93 | - |
| Viloxazine (children) | - | - | +2.79 |
| Guanfacine (children) | -2.83 | -2.08 | -4.06 |
| Methylphenidate (adults) | +1.66 | +1.60 | +4.37 |
| Amphetamines (adults) | +2.3 | - | - |
| Lisdexamfetamine (adults) | - | +3.07 | - |
| Viloxazine (adults) | - | - | +5.8 |
| Guanfacine (adults) | -10.1 | -7.73 | -6.83 |
Mean change vs. placebo in short-term randomized trials (median 7 weeks), 2025 network meta-analysis of 102 trials[3].
1The abstract reports only the lowest and highest drug for each measure, so a dash means the value was not reported there; adult estimates were rated very low certainty[3].
Sources
- •Farhat et al., The Lancet Psychiatry, 2025
Appetite, Weight and Growth in Children
Weight loss shows up within weeks. In the Vyvanse pediatric trial, children lost 0.9 to 2.5 pounds on average after 4 weeks depending on dose, while children on placebo gained 1 pound[1].
Among children aged 6 to 12 medicated 7 days a week for a year, average weight percentile fell from 60.9 to 47.2[1]. Adults lost 2.8 to 4.3 pounds over 4 weeks, depending on dose, compared with a 0.5-pound gain on placebo[1].
Height is the long-term question. The Multimodal Treatment Study of ADHD (MTA) began with 579 children diagnosed at ages 7 to 10 and followed 515 of them into early adulthood, around age 25[4]. Those with consistent or inconsistent stimulant use were 2.55 cm (about 1 inch) shorter as adults than those with negligible use, and consistent users were 2.36 cm shorter than inconsistent users[4].
These were naturalistic subgroups, not randomized groups, so families who kept children on medication may differ in other ways. The FDA label for Vyvanse calls for monitoring height and weight in children and notes that treatment may need to be interrupted when growth falls short[1]. Pillar data on how many children are diagnosed and treated are on the ADHD in children page.
Rare but Serious: Psychosis and Mania
Psychosis is rare but well documented. A 2019 study in the New England Journal of Medicine followed 221,846 adolescents and young adults with ADHD who started methylphenidate or amphetamine[5].
New-onset psychosis occurred in 0.10% of the methylphenidate group and 0.21% of the amphetamine group, a hazard ratio of 1.65 for amphetamine[5]. Across both drugs, that is roughly 1 in 660 patients[5].
Dose appears to matter. A 2024 case-control study of patients aged 16 to 35, comparing 1,374 hospitalized for new-onset psychosis or mania with 2,748 hospitalized for other reasons, found that past-month amphetamine use was associated with 2.68 times the odds of psychosis or mania[8]. At doses above 30 mg of dextroamphetamine equivalents, the odds were 5.28 times higher[8].
In the same study, past-month methylphenidate use was not associated with higher odds (odds ratio 0.91)[8]. Both studies are observational, so they show associations, not proof that the drug caused each case. Anyone having thoughts of suicide can call or text 988, the Suicide & Crisis Lifeline, at any hour.
Long-Term Side Effects: What Registry Studies Show
Registry studies are the main source of long-term data, since only four randomized trials in the largest cardiovascular review reported medium-term effects and none long-term[3]. A Swedish case-control study of 278,027 people with ADHD aged 6 to 64 tracked medication use for up to 14 years[9].
Each additional year of ADHD medication use was associated with a 4% higher risk of cardiovascular disease[9]. The increase was steeper in the first 3 years (8% per year) and then held steady[9].
The strongest associations were with hypertension and arterial disease[9]. Use for more than 5 years was associated with 1.80 times the odds of hypertension compared with nonuse[9]. Risk per year of use also rose with higher average doses[9].
The study design cannot rule out differences between people who take medication longer and those who do not. Mortality findings from the same Swedish registries are summarized in the ADHD meds overview, and adult treatment data are on the ADHD in adults page.
Misuse, Overdose Risk and Whether Side Effects Fade
Prescription stimulants carry a class-wide boxed warning for misuse, abuse, addiction and overdose, which the FDA standardized across all stimulants in 2023[6]. The FDA notes that the risk of overdose and death is higher with high doses or with non-oral use such as snorting or injecting[6].
Sharing drives much of the misuse. In the FDA's literature review, 56% to 80% of people who misused prescription stimulants got them from friends or family[6]. Past-year nonmedical use was 14% to 32% among adolescents and young adults diagnosed with ADHD[6].
Do side effects go away?
Evidence on how long individual side effects last is thin. The Vyvanse safety tables come from 4-week trials, and the cardiovascular meta-analysis had a median follow-up of 7 weeks[1][3]. Longer-term data on weight, height and blood pressure come from observational studies that cannot separate drug effects from other differences between groups.
Frequently Asked Questions
Sources & References
- Vyvanse (lisdexamfetamine dimesylate) prescribing information. U.S. Food and Drug Administration. Published 2026. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021977s052lbl.pdf [Link]
- Storebø OJ, Storm MRO, Pereira Ribeiro J, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews. Published 2023. Accessed October 2026. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009885.pub3/full [Link]
- Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. Published 2025. Accessed October 2026. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00062-8/abstract [Link]
- Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. Journal of Child Psychology and Psychiatry. Published 2017. Accessed October 2026. https://acamh.onlinelibrary.wiley.com/doi/abs/10.1111/jcpp.12684 [Link]
- Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. New England Journal of Medicine. Published 2019. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa1813751 [Link]
- U.S. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. FDA Drug Safety Communication. Published 2023. Accessed October 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions [Link]
- Strattera (atomoxetine) prescribing information. U.S. Food and Drug Administration. Published 2026. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf [Link]
- Moran LV, Skinner JP, Shinn AK, et al. Risk of incident psychosis and mania with prescription amphetamines. American Journal of Psychiatry. Published 2024. Accessed October 2026. https://psychiatryonline.org/doi/10.1176/appi.ajp.20230329 [Link]
- Zhang L, Li L, Andell P, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. Published 2024. Accessed October 2026. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2811812 [Link]